Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386(3) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers

NCT05245084 is registered in ClinicalTrials.gov with Chong Kun Dang Pharmaceutical as lead sponsor.

NCT NCT05245084
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05245084 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomized, Single Dose, 2-sequence, 4-period, Cross-over Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-386(3) With Co-administration of D013, D326, and D337 in Healthy Adult Volunteers
Lead sponsor
Chong Kun Dang Pharmaceutical
Phase
Phase 1
Overall status
Completed
Start date
March 15, 2022
Completion date
June 20, 2022
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension and dyslipidemia